Table 1.
Baseline Characteristics of Study Subjects
| Characteristics | Full Cohort (N = 246) | Baseline VAT < Sample Median (N = 123) | Baseline VAT ≥ Sample Median (N = 123) | P Value (Above vs Below Median Baseline VAT) |
|---|---|---|---|---|
| Age, median (IQR), y | 55.0 (44.0–65.0) | 52 (39–61) | 60 (50–67) | <0.001 |
| Male, N (%) | 100 (40.7) | 33 (26.8) | 67 (54.5) | <0.001 |
| White, N (%) | 222 (90.2) | 109 (88.6) | 113 (91.9) | 0.37 |
| Current smoker, N (%) | 21 (8.5) | 9 (7.3) | 12 (9.8) | 0.29 |
| Hypertension, N (%) | 88 (35.8) | 28 (22.8) | 60 (48.8) | <0.001 |
| Diabetes mellitus, N (%) | 21 (8.5) | 5 (4.1) | 16 (13) | 0.01 |
| Hyperlipidemia, N (%) | 72 (29.3) | 20 (16.3) | 52 (42.3) | <0.001 |
| Total cholesterol, mean (SD), mg/dL | 189.5 (49.4) | 187.1 (48.6) | 191.8 (50.4) | 0.66 |
| LDL, mean (SD), mg/dL | 107.5 (40.2) | 104.7 (40.3) | 110 (40.3) | 0.50 |
| Statin therapy, N (%) | 49 (19.9) | 11 (8.9) | 38 (30.9) | <0.001 |
| FRS, mean (SD) | 6 (6.4) | 3.6 (4.6) | 8.2 (7.0) | <0.001 |
| BMI, median (IQR), kg/m2 | 26.5 (23.4–31.1) | 23.8 (21.4–26.3) | 30 (26.5–33.0) | <0.001 |
| History of cancer, N (%) | 217 (88.2) | 112 (91.1) | 105 (85.4) | 0.13 |
| Prior chemotherapy, N (%) | 200 (81.3) | 103 (83.7) | 97 (78.9) | 0.22 |
| Depression, N (%)a | 12 (4.9) | 6 (4.9) | 6 (4.9) | 1.00 |
| Anxiety, N (%)a | 14 (5.7) | 4 (3.3) | 10 (8.1) | 0.001 |
| Other psychiatric disorders, N (%)a | 2 (0.8) | 1 (0.8) | 1 (0.8) | 1.00 |
Values are mean (SD), median (P25–P75), or N (%). Baseline VAT measurements were available in 246 subjects. Bold P values are <0.05.
Abbreviations: FRS, Framingham Risk Score; IQR, interquartile range; LDL, low-density lipoprotein.
a
Data on baseline psychiatric disease available in 242 subjects. Other psychiatric diseases include posttraumatic stress disorder (N = 1) and obsessive-compulsive disorder (N = 1).